News Story: Full Text
Sponsored By
Cleveland Clinic Brain Tumor and Neuro-Oncology Center
Please Click On The Above Banner For More Details
Braintumor Website

 

Tumor treating fields in pediatric high-grade glioma.

Al's Comment:

 This is proof of concept - that kids (aged 10-20) can at least tolerate the treatment. 


Posted on: 05/14/2017

Childs Nerv Syst. 2017 May 3. doi: 10.1007/s00381-017-3431-0. [Epub ahead of print]

Tumor treating fields in pediatric high-grade glioma.

Green AL1,2, Mulcahy Levy JM3,4, Vibhakar R3,4, Hemenway M3,4, Madden J3,4, Foreman N3,4, Dorris K3,4.
 
Author information:
1
    Program in Neuro-Oncology, Center for Cancer and Blood Disorders, Children's Hospital Colorado, 12800 E. 19th Ave. RC1-N, Mail Stop 8302, Aurora, CO, 80045, USA. adam.green@ucdenver.edu.
2
    Morgan Adams Foundation Pediatric Brain Tumor Research Program, Department of Pediatrics, School of Medicine, University of Colorado Anschutz Medical Campus, 12800 E. 19th Ave. RC1-N, Mail Stop 8302, Aurora, CO, 80045, USA. adam.green@ucdenver.edu.
3
    Program in Neuro-Oncology, Center for Cancer and Blood Disorders, Children's Hospital Colorado, 12800 E. 19th Ave. RC1-N, Mail Stop 8302, Aurora, CO, 80045, USA.
4
    Morgan Adams Foundation Pediatric Brain Tumor Research Program, Department of Pediatrics, School of Medicine, University of Colorado Anschutz Medical Campus, 12800 E. 19th Ave. RC1-N, Mail Stop 8302, Aurora, CO, 80045, USA.
 
Abstract
PURPOSE:
 
Tumor treating fields (TTF) are alternating electric fields applied continuously to the scalp. The treatment is approved for both primary and recurrent supratentorial adult glioblastoma but unstudied in children.
METHODS:
 
We report a feasibility case series of five pediatric high-grade glioma patients (ages 10-20 years) treated at our institution with TTF along with chemotherapy and/or radiation.
RESULTS:
 
Two patients began therapy at second recurrence and showed progressive disease. Two others were treated upfront after radiation therapy, and both showed partial responses. A fifth patient was treated at first recurrence and also showed a partial response. All five tolerated TTF well without treatment-limiting toxicities.
CONCLUSIONS:
 
The tolerability of TTF, combined with the adult data, justify a pediatric clinical trial.
PMID: 28470383 

 


Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2018 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740